Thomas Jefferson University

Thomas Pajak

TitleVolunteer Faculty
InstitutionThomas Jefferson University
DepartmentFaculty Records
Address833 Chestnut Street
Philadelphia PA 19107
vCardDownload vCard

    Collapse Research 
    Collapse research activities and funding
    U10CA032115     (SADEK, RAMSES)Apr 15, 1982 - Dec 31, 2008
    NIH
    Radiation Therapy Oncology Group-Statistical Center
    Role: Co-Principal Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Cooper JS, Fortpied C, Gregoire V, Le QT, Pajak TF, Zhang QE, Bernier J. The role of postoperative chemoradiation for oropharynx carcinoma: A critical appraisal revisited. Cancer. 2017 01 01; 123(1):12-16. PMID: 27727449.
      Citations:    
    2. Knudsen ES, Dervishaj O, Kleer CG, Pajak T, Schwartz GF, Witkiewicz AK. EZH2 and ALDH1 expression in ductal carcinoma in situ: complex association with recurrence and progression to invasive breast cancer. Cell Cycle. 2013 Jul 01; 12(13):2042-50. PMID: 23759596.
      Citations:    
    3. Knudsen ES, Pajak TF, Qeenan M, McClendon AK, Armon BD, Schwartz GF, Witkiewicz AK. Retinoblastoma and phosphate and tensin homolog tumor suppressors: impact on ductal carcinoma in situ progression. J Natl Cancer Inst. 2012 Dec 05; 104(23):1825-36. PMID: 23197489.
      Citations:    
    4. Forastiere AA, Zhang Q, Weber RS, Maor MH, Goepfert H, Pajak TF, Morrison W, Glisson B, Trotti A, Ridge JA, Thorstad W, Wagner H, Ensley JF, Cooper JS. Long-term results of RTOG 91-11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer. J Clin Oncol. 2013 Mar 01; 31(7):845-52. PMID: 23182993.
      Citations:    
    5. Cooper JS, Zhang Q, Pajak TF, Forastiere AA, Jacobs J, Saxman SB, Kish JA, Kim HE, Cmelak AJ, Rotman M, Lustig R, Ensley JF, Thorstad W, Schultz CJ, Yom SS, Ang KK. Long-term follow-up of the RTOG 9501/intergroup phase III trial: postoperative concurrent radiation therapy and chemotherapy in high-risk squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys. 2012 Dec 01; 84(5):1198-205. PMID: 22749632.
      Citations:    
    6. Baujat B, Bourhis J, Blanchard P, Overgaard J, Ang KK, Saunders M, Le Ma?tre A, Bernier J, Horiot JC, Maillard E, Pajak TF, Poulsen MG, Bourredjem A, O'Sullivan B, Dobrowsky W, Andrzej H, Skladowski K, Hay JH, Pinto LH, Fu KK, Fallai C, Sylvester R, Pignon JP. Hyperfractionated or accelerated radiotherapy for head and neck cancer. Cochrane Database Syst Rev. 2010 12 08; (12):CD002026. PMID: 21154350.
      Citations:    
    7. Rink L, Skorobogatko Y, Kossenkov AV, Belinsky MG, Pajak T, Heinrich MC, Blanke CD, von Mehren M, Ochs MF, Eisenberg B, Godwin AK. Gene expression signatures and response to imatinib mesylate in gastrointestinal stromal tumor. Mol Cancer Ther. 2009 Aug; 8(8):2172-82. PMID: 19671739.
      Citations:    
    8. Le QT, Harris J, Magliocco AM, Kong CS, Diaz R, Shin B, Cao H, Trotti A, Erler JT, Chung CH, Dicker A, Pajak TF, Giaccia AJ, Ang KK. Validation of lysyl oxidase as a prognostic marker for metastasis and survival in head and neck squamous cell carcinoma: Radiation Therapy Oncology Group trial 90-03. J Clin Oncol. 2009 Sep 10; 27(26):4281-6. PMID: 19667273.
      Citations:    
    9. Michiels S, Le Ma?tre A, Buyse M, Burzykowski T, Maillard E, Bogaerts J, Vermorken JB, Budach W, Pajak TF, Ang KK, Bourhis J, Pignon JP. Surrogate endpoints for overall survival in locally advanced head and neck cancer: meta-analyses of individual patient data. Lancet Oncol. 2009 Apr; 10(4):341-50. PMID: 19246242.
      Citations:    
    10. Trotti A, Pajak TF, Ridge JA. Treatment of head and neck cancer. N Engl J Med. 2008 Mar 06; 358(10):1076; author reply 1077-8. PMID: 18326079.
      Citations:    
    11. Coyne JC, Pajak TF, Harris J, Konski A, Movsas B, Ang K, Watkins Bruner D. Emotional well-being does not predict survival in head and neck cancer patients: a Radiation Therapy Oncology Group study. Cancer. 2007 Dec 01; 110(11):2568-75. PMID: 17955501.
      Citations:    
    12. Siddiqui F, Pajak TF, Watkins-Bruner D, Konski AA, Coyne JC, Gwede CK, Garden AS, Spencer SA, Jones C, Movsas B. Pretreatment quality of life predicts for locoregional control in head and neck cancer patients: a radiation therapy oncology group analysis. Int J Radiat Oncol Biol Phys. 2008 Feb 01; 70(2):353-60. PMID: 17889449.
      Citations:    
    13. Machtay M, Pajak TF, Suntharalingam M, Shenouda G, Hershock D, Stripp DC, Cmelak AJ, Schulsinger A, Fu KK. Radiotherapy with or without erythropoietin for anemic patients with head and neck cancer: a randomized trial of the Radiation Therapy Oncology Group (RTOG 99-03). Int J Radiat Oncol Biol Phys. 2007 Nov 15; 69(4):1008-17. PMID: 17716826.
      Citations:    
    14. Calvin DP, Hammond ME, Pajak TF, Trotti AM, Meredith RF, Rotman M, Jones CU, Byhardt RW, Demas WF, Ang KK, Fu KK. Microvessel density >or=60 does not predict for outcome after radiation treatment for locally advanced head and neck squamous cell carcinoma: results of a correlative study from the Radiation Therapy Oncology Group (RTOG) 90-03 Trial. Am J Clin Oncol. 2007 Aug; 30(4):406-19. PMID: 17762442.
      Citations:    
    15. Trotti A, Pajak TF, Gwede CK, Paulus R, Cooper J, Forastiere A, Ridge JA, Watkins-Bruner D, Garden AS, Ang KK, Curran W. TAME: development of a new method for summarising adverse events of cancer treatment by the Radiation Therapy Oncology Group. Lancet Oncol. 2007 Jul; 8(7):613-24. PMID: 17543584.
      Citations:    
    16. Bourhis J, Overgaard J, Audry H, Ang KK, Saunders M, Bernier J, Horiot JC, Le Ma?tre A, Pajak TF, Poulsen MG, O'Sullivan B, Dobrowsky W, Hliniak A, Skladowski K, Hay JH, Pinto LH, Fallai C, Fu KK, Sylvester R, Pignon JP. Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis. Lancet. 2006 Sep 02; 368(9538):843-54. PMID: 16950362.
      Citations:    
    17. Konski AA, Pajak TF, Movsas B, Coyne J, Harris J, Gwede C, Garden A, Spencer S, Jones C, Watkins-Bruner D. Disadvantage of men living alone participating in Radiation Therapy Oncology Group head and neck trials. J Clin Oncol. 2006 Sep 01; 24(25):4177-83. PMID: 16943534.
      Citations:    
    18. Khuri FR, Lee JJ, Lippman SM, Kim ES, Cooper JS, Benner SE, Winn R, Pajak TF, Williams B, Shenouda G, Hodson I, Fu K, Shin DM, Vokes EE, Feng L, Goepfert H, Hong WK. Randomized phase III trial of low-dose isotretinoin for prevention of second primary tumors in stage I and II head and neck cancer patients. J Natl Cancer Inst. 2006 Apr 05; 98(7):441-50. PMID: 16595780.
      Citations:    
    19. Bernier J, Cooper JS, Pajak TF, van Glabbeke M, Bourhis J, Forastiere A, Ozsahin EM, Jacobs JR, Jassem J, Ang KK, Lef?bvre JL. Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501). Head Neck. 2005 Oct; 27(10):843-50. PMID: 16161069.
      Citations:    
    20. Cooper JS, Pajak TF, Forastiere AA, Jacobs J, Campbell BH, Saxman SB, Kish JA, Kim HE, Cmelak AJ, Rotman M, Machtay M, Ensley JF, Chao KS, Schultz CJ, Lee N, Fu KK. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med. 2004 May 06; 350(19):1937-44. PMID: 15128893.
      Citations:    
    21. Trotti A, Garden A, Warde P, Symonds P, Langer C, Redman R, Pajak TF, Fleming TR, Henke M, Bourhis J, Rosenthal DI, Junor E, Cmelak A, Sheehan F, Pulliam J, Devitt-Risse P, Fuchs H, Chambers M, O'Sullivan B, Ang KK. A multinational, randomized phase III trial of iseganan HCl oral solution for reducing the severity of oral mucositis in patients receiving radiotherapy for head-and-neck malignancy. Int J Radiat Oncol Biol Phys. 2004 Mar 01; 58(3):674-81. PMID: 14967419.
      Citations:    
    22. Forastiere AA, Goepfert H, Maor M, Pajak TF, Weber R, Morrison W, Glisson B, Trotti A, Ridge JA, Chao C, Peters G, Lee DJ, Leaf A, Ensley J, Cooper J. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med. 2003 Nov 27; 349(22):2091-8. PMID: 14645636.
      Citations:    
    23. Hanks GE, Pajak TF, Porter A, Grignon D, Brereton H, Venkatesan V, Horwitz EM, Lawton C, Rosenthal SA, Sandler HM, Shipley WU. Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02. J Clin Oncol. 2003 Nov 01; 21(21):3972-8. PMID: 14581419.
      Citations:    
    24. White J, Morrow M, Moughan J, Owen J, Pajak T, DesHarnais S, Winchester DP, Wilson JF. Compliance with breast-conservation standards for patients with early-stage breast carcinoma. Cancer. 2003 Feb 15; 97(4):893-904. PMID: 12569588.
      Citations:    
    25. Milanes-Yearsley M, Hammond ME, Pajak TF, Cooper JS, Chang C, Griffin T, Nelson D, Laramore G, Pilepich M. Tissue micro-array: a cost and time-effective method for correlative studies by regional and national cancer study groups. Mod Pathol. 2002 Dec; 15(12):1366-73. PMID: 12481019.
      Citations:    
    26. Ang KK, Berkey BA, Pajak TF, Fu KK. In response to Drs. Dubben, Beck-Bornholdt, and Llogie. Int J Radiat Oncol Biol Phys. 2002 Mar 15; 52(4):1148-50. PMID: 11958923.
      Citations:    
    27. Minsky BD, Pajak TF, Ginsberg RJ, Pisansky TM, Martenson J, Komaki R, Okawara G, Rosenthal SA, Kelsen DP. INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol. 2002 Mar 01; 20(5):1167-74. PMID: 11870157.
      Citations:    
    28. Khuri FR, Kim ES, Lee JJ, Winn RJ, Benner SE, Lippman SM, Fu KK, Cooper JS, Vokes EE, Chamberlain RM, Williams B, Pajak TF, Goepfert H, Hong WK. The impact of smoking status, disease stage, and index tumor site on second primary tumor incidence and tumor recurrence in the head and neck retinoid chemoprevention trial. Cancer Epidemiol Biomarkers Prev. 2001 Aug; 10(8):823-9. PMID: 11489748.
      Citations:    
    29. Willett C, Ajani J, Kelsen D, Sigurdson E, Abrams R, Berkey B, Benetz M, Crane C, Gaspar L, Goodyear MD, Gunderson L, Haddock M, Hoffmann J, Janjan N, John M, Kachnic L, Krieg R, Landry J, Meropol N, Minsky B, Mitchell E, Mohiuddin M, Moulder J, Myerson R, Noyes D, Pajak TF, Raben D, Regine W, Rich T, Robertson JM, Russell A, Skibber J, Kim P. Radiation Therapy Oncology Group. Research Plan 2002-2006. Gastrointestinal Cancer Committee. Int J Radiat Oncol Biol Phys. 2001; 51(3 Suppl 2):19-27. PMID: 11641011.
      Citations:    
    30. Ang K, Weber R, Vokes E, Trotti A, Chapman D, Cooper J, Forastiere A, Fu KK, Hammond E, Khuri F, Leveque FS, Leupold N, Eisbruch A, Mack C, Mukherji S, Pajak TF, Ridge JA. Radiation Therapy Oncology Group. Research Plan 2002-2006. Head and Neck Cancer Committee. Int J Radiat Oncol Biol Phys. 2001; 51(3 Suppl 2):39-43. PMID: 11641013.
      Citations:    
    31. Okunieff P, Hammond E, Grignon D, Langer C, Pajak TF, Ang K, Bruner DW, Travis E, Greven K, Guha A, Moulder J, Pollack A, Scarantino C, Sneige N, Watson J, Amin M, Bondy M, Chakravarti A, Chapman JD, Dicker A, Harris J, Koch W, Komaki R, Lange C, McBride W, Mitchell J, Milas L, Movsas B, Pandya K, Pienta K, Regine W, Ritter M, Rubin P, Safran H, Sauter E, Schell M, Stevens C, Trotti A, Vikram B. Radiation Therapy Oncology Group. Research Plan 2002-2006. Translational Research Program. Int J Radiat Oncol Biol Phys. 2001; 51(3 Suppl 2):75-87. PMID: 11641020.
      Citations:    
    32. Lu J, Pajak TF. Statistical power for a long-term survival trial with a time-dependent treatment effect. Control Clin Trials. 2000 Dec; 21(6):561-73. PMID: 11146150.
      Citations:    
    33. Fu KK, Pajak TF, Trotti A, Jones CU, Spencer SA, Phillips TL, Garden AS, Ridge JA, Cooper JS, Ang KK. A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003. Int J Radiat Oncol Biol Phys. 2000 Aug 01; 48(1):7-16. PMID: 10924966.
      Citations:    
    34. Pajak TF, Clark GM, Sargent DJ, McShane LM, Hammond ME. Statistical issues in tumor marker studies. Arch Pathol Lab Med. 2000 Jul; 124(7):1011-5. PMID: 10888777.
      Citations:    
    35. Hammond ME, Fitzgibbons PL, Compton CC, Grignon DJ, Page DL, Fielding LP, Bostwick D, Pajak TF. College of American Pathologists Conference XXXV: solid tumor prognostic factors-which, how and so what? Summary document and recommendations for implementation. Cancer Committee and Conference Participants. Arch Pathol Lab Med. 2000 Jul; 124(7):958-65. PMID: 10888771.
      Citations:    
    36. Cox JD, Pajak TF, Curran WJ. Methodology and research by the Radiation Therapy Oncology Group (RTOG). Rays. 2000 Jul-Sep; 25(3):309-12. PMID: 11367895.
      Citations:    
    37. Bostwick DG, Grignon DJ, Hammond ME, Amin MB, Cohen M, Crawford D, Gospadarowicz M, Kaplan RS, Miller DS, Montironi R, Pajak TF, Pollack A, Srigley JR, Yarbro JW. Prognostic factors in prostate cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med. 2000 Jul; 124(7):995-1000. PMID: 10888774.
      Citations:    
    38. Cox JD, Fu KK, Pajak TF, Cooper JS, Ang KK. Radiation Therapy Oncology Group (RTOG) trials for head and neck cancer. Rays. 2000 Jul-Sep; 25(3):321-3. PMID: 11367897.
      Citations:    
    39. Wolf GT, Forastiere A, Ang K, Brockstein B, Conley B, Goepfert H, Kraus D, Lefebvre JL, Pajak TF, Pfister D, Urba S. Workshop report: organ preservation strategies in advanced head and neck cancer--current status and future directions. Head Neck. 1999 Dec; 21(8):689-93. PMID: 10562680.
      Citations:    
    40. Jacobs JR, Logemann J, Pajak TF, Pauloski BR, Collins S, Casiano RR, Schuller DE. Failure of cricopharyngeal myotomy to improve dysphagia following head and neck cancer surgery. Arch Otolaryngol Head Neck Surg. 1999 Sep; 125(9):942-6. PMID: 10488976.
      Citations:    
    41. Bonin SR, Pajak TF, Russell AH, Coia LR, Paris KJ, Flam MS, Sauter ER. Overexpression of p53 protein and outcome of patients treated with chemoradiation for carcinoma of the anal canal: a report of randomized trial RTOG 87-04. Radiation Therapy Oncology Group. Cancer. 1999 Mar 15; 85(6):1226-33. PMID: 10189126.
      Citations:    
    42. Minsky BD, Neuberg D, Kelsen DP, Pisansky TM, Ginsberg RJ, Pajak T, Salter M, Benson AB. Final report of Intergroup Trial 0122 (ECOG PE-289, RTOG 90-12): Phase II trial of neoadjuvant chemotherapy plus concurrent chemotherapy and high-dose radiation for squamous cell carcinoma of the esophagus. Int J Radiat Oncol Biol Phys. 1999 Feb 01; 43(3):517-23. PMID: 10078631.
      Citations:    
    43. Epstein BE, Pajak TF, Haulk TL, Herpst JM, Order SE, Abrams RA. Metastatic nonresectable fibrolamellar hepatoma: prognostic features and natural history. Am J Clin Oncol. 1999 Feb; 22(1):22-8. PMID: 10025374.
      Citations:    
    44. Kelsen DP, Ginsberg R, Pajak TF, Sheahan DG, Gunderson L, Mortimer J, Estes N, Haller DG, Ajani J, Kocha W, Minsky BD, Roth JA. Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl J Med. 1998 Dec 31; 339(27):1979-84. PMID: 9869669.
      Citations:    
    45. Cooper JS, Pajak TF, Forastiere A, Jacobs J, Fu KK, Ang KK, Laramore GE, Al-Sarraf M. Precisely defining high-risk operable head and neck tumors based on RTOG #85-03 and #88-24: targets for postoperative radiochemotherapy? Head Neck. 1998 Oct; 20(7):588-94. PMID: 9744457.
      Citations:    
    46. Vokes EE, Pajak TF. Enhancing the therapeutic index of concomitant chemoradiotherapy for head and neck cancer. Ann Oncol. 1998 May; 9(5):471-3. PMID: 9653485.
      Citations:    
    47. Abrams RA, Pajak TF, Haulk TL, Flam M, Asbell SO. Survival results among patients with alpha-fetoprotein-positive, unresectable hepatocellular carcinoma: analysis of three sequential treatments of the RTOG and Johns Hopkins Oncology Center. Cancer J Sci Am. 1998 May-Jun; 4(3):178-84. PMID: 9612600.
      Citations:    
    48. Riese NE, Buswell L, Noll L, Pajak TF, Stetz J, Lee DJ, Coleman CN. Pharmacokinetic monitoring and dose modification of etanidazole in the RTOG 85-27 phase III head and neck trial. Int J Radiat Oncol Biol Phys. 1997 Nov 01; 39(4):855-8. PMID: 9369134.
      Citations:    
    49. Scott C, Sause WT, Byhardt R, Marcial V, Pajak TF, Herskovic A, Cox JD. Recursive partitioning analysis of 1592 patients on four Radiation Therapy Oncology Group studies in inoperable non-small cell lung cancer. Lung Cancer. 1997 Jun; 17 Suppl 1:S59-74. PMID: 9213303.
      Citations:    
    50. Al-Sarraf M, Pajak TF, Byhardt RW, Beitler JJ, Salter MM, Cooper JS. Postoperative radiotherapy with concurrent cisplatin appears to improve locoregional control of advanced, resectable head and neck cancers: RTOG 88-24. Int J Radiat Oncol Biol Phys. 1997 Mar 01; 37(4):777-82. PMID: 9128951.
      Citations:    
    51. Grignon DJ, Caplan R, Sarkar FH, Lawton CA, Hammond EH, Pilepich MV, Forman JD, Mesic J, Fu KK, Abrams RA, Pajak TF, Shipley WU, Cox JD. p53 status and prognosis of locally advanced prostatic adenocarcinoma: a study based on RTOG 8610. J Natl Cancer Inst. 1997 Jan 15; 89(2):158-65. PMID: 8998185.
      Citations:    
    52. Flam M, John M, Pajak TF, Petrelli N, Myerson R, Doggett S, Quivey J, Rotman M, Kerman H, Coia L, Murray K. Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study. J Clin Oncol. 1996 Sep; 14(9):2527-39. PMID: 8823332.
      Citations:    
    53. John M, Pajak T, Flam M, Hoffman J, Markoe A, Wolkov H, Paris K. Dose escalation in chemoradiation for anal cancer: preliminary results of RTOG 92-08. Cancer J Sci Am. 1996 Jul-Aug; 2(4):205-11. PMID: 9166533.
      Citations:    
    54. Fu KK, Cooper JS, Marcial VA, Laramore GE, Pajak TF, Jacobs J, Al-Sarraf M, Forastiere AA, Cox JD. Evolution of the Radiation Therapy Oncology Group clinical trials for head and neck cancer. Int J Radiat Oncol Biol Phys. 1996 Jun 01; 35(3):425-38. PMID: 8655364.
      Citations:    
    55. Rotman M, Pajak TF, Choi K, Clery M, Marcial V, Grigsby PW, Cooper J, John M. Prophylactic extended-field irradiation of para-aortic lymph nodes in stages IIB and bulky IB and IIA cervical carcinomas. Ten-year treatment results of RTOG 79-20. JAMA. 1995 Aug 02; 274(5):387-93. PMID: 7616634.
      Citations:    
    56. Caplan RJ, Pajak TF, Cox JD. In response to Bentzen et al., IJROBP 32:1531-1534; 1995. Int J Radiat Oncol Biol Phys. 1995 Jul 30; 32(5):1547. PMID: 7635803.
      Citations:    
    57. Cosmatos D, Pajak TF. Statistical response to Dr. J. M. Brown, IJROBP 32:883-885; 1995. Int J Radiat Oncol Biol Phys. 1995 Jul 15; 32(4):1265-6. PMID: 7607955.
      Citations:    
    58. Fu KK, Pajak TF, Marcial VA, Ortiz HG, Rotman M, Asbell SO, Coia LR, Vora NL, Byhardt R, Rubin P, et al. Late effects of hyperfractionated radiotherapy for advanced head and neck cancer: long-term follow-up results of RTOG 83-13. Int J Radiat Oncol Biol Phys. 1995 Jun 15; 32(3):577-88. PMID: 7790242.
      Citations:    
    59. Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC) Int J Radiat Oncol Biol Phys. 1995 Mar 30; 31(5):1341-6. PMID: 7713792.
      Citations:    
    60. Scott CB, Pajak TF. LENT: a good beginning but... Int J Radiat Oncol Biol Phys. 1995 Mar 30; 31(5):1347-8. PMID: 7713793.
      Citations:    
    61. Nag S, Owen JB, Farnan N, Pajak TF, Martinez A, Porter A, Blasko J, Harrison LB. Survey of brachytherapy practice in the United States: a report of the Clinical Research Committee of the American Endocurietherapy Society. Int J Radiat Oncol Biol Phys. 1995 Jan 01; 31(1):103-7. PMID: 7995739.
      Citations:    
    62. Benner SE, Pajak TF, Stetz J, Lippman SM, Hong WK, Schantz SP, Gallagher MJ, Shenouda G. Toxicity of isotretinoin in a chemoprevention trial to prevent second primary tumors following head and neck cancer. J Natl Cancer Inst. 1994 Dec 07; 86(23):1799-801. PMID: 7966422.
      Citations:    
    63. Sause WT, Pajak TF, Noyes RD, Dobelbower R, Fischbach J, Doggett S, Mohiuddin M. Evaluation of preoperative radiation therapy in operable colorectal cancer. Ann Surg. 1994 Nov; 220(5):668-75. PMID: 7979616.
      Citations:    
    64. Hanks GE, Perez CA, Kozar M, Asbell SO, Pilepich MV, Pajak TF. PSA confirmation of cure at 10 years of T1B, T2, N0, M0 prostate cancer patients treated in RTOG protocol 7706 with external beam irradiation. Int J Radiat Oncol Biol Phys. 1994 Sep 30; 30(2):289-92. PMID: 7523341.
      Citations:    
    65. Caplan RJ, Pajak TF, Cox JD. Analysis of the probability and risk of cause-specific failure. Int J Radiat Oncol Biol Phys. 1994 Jul 30; 29(5):1183-6. PMID: 7521864.
      Citations:    
    66. Fu KK, Hammond E, Pajak TF, Clery M, Doggett RL, Byhardt RW, McDonald S, Cooper JS. Flow cytometric quantification of the proliferation-associated nuclear antigen p105 and DNA content in advanced head & neck cancers: results of RTOG 91-08. Int J Radiat Oncol Biol Phys. 1994 Jul 01; 29(4):661-71. PMID: 7913703.
      Citations:    
    67. Harrington D, Crowley J, George SL, Pajak T, Redmond C, Wieand S. The case against independent monitoring committees. Stat Med. 1994 Jul 15-30; 13(13-14):1411-4. PMID: 7973220.
      Citations:    
    68. Corn BW, Hanlon AL, Pajak TF, Owen J, Hanks GE. Technically accurate intracavitary insertions improve pelvic control and survival among patients with locally advanced carcinoma of the uterine cervix. Gynecol Oncol. 1994 Jun; 53(3):294-300. PMID: 8206401.
      Citations:    
    69. Komaki R, Pajak TF, Marcial VA, Rotman M, Grigsby PW, Leibel SA, Eifel PJ. Twice-daily fractionation of external irradiation with brachytherapy in bulky carcinoma of the cervix. Phase I/II study of the Radiation Therapy Oncology Group 88-05. Cancer. 1994 May 15; 73(10):2619-25. PMID: 8174061.
      Citations:    
    70. Jacobs JR, Casiano RR, Schuller DE, Pajak TF, Laramore GE, al-Sarraf M. Chemotherapy as predictor of compliance. J Surg Oncol. 1994 Mar; 55(3):143-8. PMID: 8176922.
      Citations:    
    71. Cox JD, Sause WT, Byhardt RW, Komaki R, Perez CA, Pajak TF. Dose intensity of radiation therapy in non-small cell carcinoma of the lung: a review of RTOG data and strategies. Lung Cancer. 1994 Mar; 10 Suppl 1:S161-6. PMID: 8087506.
      Citations:    
    72. Benner SE, Pajak TF, Lippman SM, Earley C, Hong WK. Prevention of second primary tumors with isotretinoin in patients with squamous cell carcinoma of the head and neck: long-term follow-up. J Natl Cancer Inst. 1994 Jan 19; 86(2):140-1. PMID: 8271298.
      Citations:    
    73. Fu KK, Cox JD, Pajak TF, Marcial VA, Coia LR, Mohiuddin M, Selim HM, Byhardt RW, McDonald S, Ortiz HG, et al. Carcinomas of the oropharynx treated with hyperfractionated radiation therapy on Radiation Therapy Oncology Group Protocol 8313. Recent Results Cancer Res. 1994; 134:145-54. PMID: 8153430.
      Citations:    
    74. Komaki R, Pajak TF, Byhardt RW, Emami B, Asbell SO, Roach M, Pedersen JE, Curran WJ, Lattin P, Russell AH, et al. Analysis of early and late deaths on RTOG non-small cell carcinoma of the lung trials: comparison with CALGB 8433. Lung Cancer. 1993 Dec; 10(3-4):189-97. PMID: 8075966.
      Citations:    
    75. Byhardt RW, Martin L, Pajak TF, Shin KH, Emami B, Cox JD. The influence of field size and other treatment factors on pulmonary toxicity following hyperfractionated irradiation for inoperable non-small cell lung cancer (NSCLC)--analysis of a Radiation Therapy Oncology Group (RTOG) protocol. Int J Radiat Oncol Biol Phys. 1993 Oct 20; 27(3):537-44. PMID: 8226146.
      Citations:    
    76. Cox JD, Pajak TF, Asbell S, Russell AH, Pederson J, Byhardt RW, Emami B, Roach M. Interruptions of high-dose radiation therapy decrease long-term survival of favorable patients with unresectable non-small cell carcinoma of the lung: analysis of 1244 cases from 3 Radiation Therapy Oncology Group (RTOG) trials. Int J Radiat Oncol Biol Phys. 1993 Oct 20; 27(3):493-8. PMID: 8226140.
      Citations:    
    77. Lazarus CL, Logemann JA, Rademaker AW, Kahrilas PJ, Pajak T, Lazar R, Halper A. Effects of bolus volume, viscosity, and repeated swallows in nonstroke subjects and stroke patients. Arch Phys Med Rehabil. 1993 Oct; 74(10):1066-70. PMID: 8215858.
      Citations:    
    78. Marcial VA, Pajak TF, Rotman M, Brady LW, Amato D. "Compensated" split-course versus continuous radiation therapy of carcinoma of the tonsillar fossa. Final results of a prospective randomized clinical trial of the Radiation Therapy Oncology Group. Am J Clin Oncol. 1993 Oct; 16(5):389-96. PMID: 8213620.
      Citations:    
    79. Byhardt RW, Pajak TF, Emami B, Herskovic A, Doggett RS, Olsen LA. A phase I/II study to evaluate accelerated fractionation via concomitant boost for squamous, adeno, and large cell carcinoma of the lung: report of Radiation Therapy Oncology Group 84-07. Int J Radiat Oncol Biol Phys. 1993 Jun 15; 26(3):459-68. PMID: 8390420.
      Citations:    
    80. Lanciano RM, Pajak TF, Martz K, Hanks GE. The influence of treatment time on outcome for squamous cell cancer of the uterine cervix treated with radiation: a patterns-of-care study. Int J Radiat Oncol Biol Phys. 1993 Feb 15; 25(3):391-7. PMID: 8436516.
      Citations:    
    81. Cox JD, Pajak TF, Marcial VA, Coia L, Mohiuddin M, Fu KK, Selim HM, Byhardt RW, Rubin P, Ortiz HG, et al. Interruptions adversely affect local control and survival with hyperfractionated radiation therapy of carcinomas of the upper respiratory and digestive tracts. New evidence for accelerated proliferation from Radiation Therapy Oncology Group Protocol 8313. Cancer. 1992 Jun 01; 69(11):2744-8. PMID: 1571904.
      Citations:    
    82. Diener-West M, Pajak TF, Bauer M, Cox JD. Randomized dose-searching phase ILE/II trials of fractionation in radiation therapy for cancer. J Natl Cancer Inst. 1991 Aug 07; 83(15):1065-71. PMID: 1875413.
      Citations:    
    83. Cox JD, Pajak TF, Herskovic A, Urtasun R, Podolsky WJ, Seydel HG. Five-year survival after hyperfractionated radiation therapy for non-small-cell carcinoma of the lung (NSCCL): results of RTOG protocol 81-08. Am J Clin Oncol. 1991 Aug; 14(4):280-4. PMID: 1650526.
      Citations:    
    84. Wasserman TH, Phillips TL, Hanks GE, Order SE, Perez CA, Pajak TF, Pakuris E, Brady LW, Leibel SA, Cox JD. The Radiation Therapy Oncology Group: an update of clinical research activities. Int J Radiat Oncol Biol Phys. 1991 Jun; 20(6):1383-91. PMID: 2045315.
      Citations:    
    85. Cox JD, Pajak TF, Marcial VA, Coia L, Mohiuddin M, Fu KK, Selim H, Rubin P, Ortiz H. ASTRO plenary: interfraction interval is a major determinant of late effects, with hyperfractionated radiation therapy of carcinomas of upper respiratory and digestive tracts: results from Radiation Therapy Oncology Group protocol 8313. Int J Radiat Oncol Biol Phys. 1991 Jun; 20(6):1191-5. PMID: 2045293.
      Citations:    
    86. Order S, Pajak T, Leibel S, Asbell S, Leichner P, Ettinger D, Stillwagon G, Herpst J, Haulk T, Kopher K, et al. A randomized prospective trial comparing full dose chemotherapy to 131I antiferritin: an RTOG study. Int J Radiat Oncol Biol Phys. 1991 May; 20(5):953-63. PMID: 1850722.
      Citations:    
    87. Perez CA, Pajak T, Emami B, Hornback NB, Tupchong L, Rubin P. Randomized phase III study comparing irradiation and hyperthermia with irradiation alone in superficial measurable tumors. Final report by the Radiation Therapy Oncology Group. Am J Clin Oncol. 1991 Apr; 14(2):133-41. PMID: 1903023.
      Citations:    
    88. Jacobs JR, Fu KK, Lowry LD, Scotte Doggett RL, Pajak TF, Al-Sarraf M. 5-year results of cisplatin and fluorouracil infusion in head and neck cancer. Arch Otolaryngol Head Neck Surg. 1991 Mar; 117(3):288-91. PMID: 1998567.
      Citations:    
    89. Pennell RG, Needleman L, Pajak T, Baltarowich O, Vilaro M, Goldberg BB, Kurtz AB. Prospective comparison of vaginal and abdominal sonography in normal early pregnancy. J Ultrasound Med. 1991 Feb; 10(2):63-7. PMID: 2020050.
      Citations:    
    90. Pajak TF, Laramore GE, Marcial VA, Fazekas JT, Cooper J, Rubin P, Curran WJ, Davis LW. Elapsed treatment days--a critical item for radiotherapy quality control review in head and neck trials: RTOG report. Int J Radiat Oncol Biol Phys. 1991 Jan; 20(1):13-20. PMID: 1993621.
      Citations:    
    91. Jacobs JR, Pajak TF, Weymuller E, Sessions D, Schuller DE. Development of surgical quality-control mechanisms in large-scale prospective trials: head and neck intergroup report. Head Neck. 1991 Jan-Feb; 13(1):28-32. PMID: 1989927.
      Citations:    
    92. Marcial VA, Pajak TF, Mohiuddin M, Cooper JS, al Sarraf M, Mowry PA, Curran W, Crissman J, Rodr?guez M, V?lez-Garc?a E. Concomitant cisplatin chemotherapy and radiotherapy in advanced mucosal squamous cell carcinoma of the head and neck. Long-term results of the Radiation Therapy Oncology Group study 81-17. Cancer. 1990 Nov 01; 66(9):1861-8. PMID: 2224782.
      Citations:    
    93. Cox JD, Azarnia N, Byhardt RW, Shin KH, Emami B, Pajak TF. A randomized phase I/II trial of hyperfractionated radiation therapy with total doses of 60.0 Gy to 79.2 Gy: possible survival benefit with greater than or equal to 69.6 Gy in favorable patients with Radiation Therapy Oncology Group stage III non-small-cell lung carcinoma: report of Radiation Therapy Oncology Group 83-11. J Clin Oncol. 1990 Sep; 8(9):1543-55. PMID: 2167952.
      Citations:    
    94. al-Sarraf M, Pajak TF, Cooper JS, Mohiuddin M, Herskovic A, Ager PJ. Chemo-radiotherapy in patients with locally advanced nasopharyngeal carcinoma: a radiation therapy oncology group study. J Clin Oncol. 1990 Aug; 8(8):1342-51. PMID: 2199621.
      Citations:    
    95. Dewhirst MW, Phillips TL, Samulski TV, Stauffer P, Shrivastava P, Paliwal B, Pajak T, Gillim M, Sapozink M, Myerson R, et al. RTOG quality assurance guidelines for clinical trials using hyperthermia. Int J Radiat Oncol Biol Phys. 1990 May; 18(5):1249-59. PMID: 2347733.
      Citations:    
    96. Cox JD, Pajak TF, Marcial VA, Hanks GE, Mohiuddin M, Fu KK, Byhardt RW, Rubin P. Dose-response for local control with hyperfractionated radiation therapy in advanced carcinomas of the upper aerodigestive tracts: preliminary report of radiation therapy oncology group protocol 83-13. Int J Radiat Oncol Biol Phys. 1990 Mar; 18(3):515-21. PMID: 2180866.
      Citations:    
    97. Pajak TF, Guse CE. Are cancer researchers speaking the same language? Int J Radiat Oncol Biol Phys. 1990 Mar; 18(3):707. PMID: 2318706.
      Citations:    
    98. Griffin TW, Pajak TF, Maor MH, Laramore GE, Hendrickson FR, Parker RG, Thomas FJ, Davis LW. Mixed neutron/photon irradiation of unresectable squamous cell carcinomas of the head and neck: the final report of a randomized cooperative trial. Int J Radiat Oncol Biol Phys. 1989 Nov; 17(5):959-65. PMID: 2681103.
      Citations:    
    99. Wallner PE, Lustig RA, Pajak TF, Robinson G, Davis LW, Perez CA, Seydel HG, Marcial VA, Laramore GE. Impact of initial quality control review on study outcome in lung and head/neck cancer studies--review of the Radiation Therapy Oncology Group experience. Int J Radiat Oncol Biol Phys. 1989 Oct; 17(4):893-900. PMID: 2674086.
      Citations:    
    100. Cooper JS, Pajak TF, Rubin P, Tupchong L, Brady LW, Leibel SA, Laramore GE, Marcial VA, Davis LW, Cox JD, et al. Second malignancies in patients who have head and neck cancer: incidence, effect on survival and implications based on the RTOG experience. Int J Radiat Oncol Biol Phys. 1989 Sep; 17(3):449-56. PMID: 2674073.
      Citations:    
    101. Koh WJ, Laramore G, Griffin T, Russell K, Griffin B, Parker R, Davis L, Pajak TF. Fast neutron radiation for inoperable and recurrent salivary gland cancers. Am J Clin Oncol. 1989 Aug; 12(4):316-9. PMID: 2667321.
      Citations:    
    102. Jacobs JR, Pajak TF, al-Sarraf M, Kinzie J, Stetz J, Davis LW, Leibel S, Laramore GE. Chemotherapy following surgery for head and neck cancer. A Radiation Therapy Oncology Group Study. Am J Clin Oncol. 1989 Jun; 12(3):185-9. PMID: 2499175.
      Citations:    
    103. Jacobs JR, Pajak TF, Snow JB, Lowry LD, Kramer S. Surgical quality control in head and neck cancer. Study 73-03 of the Radiation Therapy Oncology Group. Arch Otolaryngol Head Neck Surg. 1989 Apr; 115(4):489-93. PMID: 2647106.
      Citations:    
    104. Schuller DE, Laramore G, Al-Sarraf M, Jacobs J, Pajak TF. Combined therapy for resectable head and neck cancer. A phase 3 intergroup study. Arch Otolaryngol Head Neck Surg. 1989 Mar; 115(3):364-8. PMID: 2644954.
      Citations:    
    105. Shrivastava P, Luk K, Oleson J, Dewhirst M, Pajak T, Paliwal B, Perez C, Sapareto S, Saylor T, Steeves R. Hyperthermia quality assurance guidelines. Int J Radiat Oncol Biol Phys. 1989 Mar; 16(3):571-87. PMID: 2921160.
      Citations:    
    106. Perez CA, Gillespie B, Pajak T, Hornback NB, Emami B, Rubin P. Quality assurance problems in clinical hyperthermia and their impact on therapeutic outcome: a Report by the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys. 1989 Mar; 16(3):551-8. PMID: 2646257.
      Citations:    
    107. Lee DJ, Pajak TF, Stetz J, Order SE, Weissberg JB, Fischer JJ. A phase I/II study of the hypoxic cell sensitizer misonidazole as an adjunct to high fractional dose radiotherapy in patients with unresectable squamous cell carcinoma of the head and neck: a RTOG randomized study (#79-04). Int J Radiat Oncol Biol Phys. 1989 Feb; 16(2):465-70. PMID: 2646255.
      Citations:    
    108. Griffin TW, Pajak TF, Laramore GE, Duncan W, Richter MP, Hendrickson FR, Maor MH. Neutron vs photon irradiation of inoperable salivary gland tumors: results of an RTOG-MRC Cooperative Randomized Study. Int J Radiat Oncol Biol Phys. 1988 Nov; 15(5):1085-90. PMID: 2846479.
      Citations:    
    109. Cornwell GG, Pajak TF, Kochwa S, McIntyre OR, Glowienka LP, Brunner K, Rafla S, Coleman M, Cooper MR, Henderson E, et al. Vincristine and prednisone prolong the survival of patients receiving intravenous or oral melphalan for multiple myeloma: Cancer and Leukemia Group B experience. J Clin Oncol. 1988 Sep; 6(9):1481-90. PMID: 3047338.
      Citations:    
    110. Laramore GE, Altschuler MD, Banks G, Kalet IJ, Pajak TF, Schultheiss TE, Zink S. Applications of data bases and AI/expert systems in radiation therapy. Am J Clin Oncol. 1988 Jun; 11(3):387-93. PMID: 3289369.
      Citations:    
    111. Marcial VA, Pajak TF, Kramer S, Davis LW, Stetz J, Laramore GE, Jacobs JR, Al-Sarraf M, Brady LW. Radiation Therapy Oncology Group (RTOG) studies in head and neck cancer. Semin Oncol. 1988 Feb; 15(1):39-60. PMID: 3278390.
      Citations:    
    112. Brady L, Kramer S, Wasserman TH, Keiser M, Davis L, Pajak TF, Cox J, Rubin P, Griffin T, Perez C, et al. The Radiation Therapy Oncology Group: an outline of clinical research activities. Int J Radiat Oncol Biol Phys. 1988; 14 Suppl 1:S3-12. PMID: 3292480.
      Citations:    
    113. Fazekas J, Pajak TF, Wasserman T, Marcial V, Davis L, Kramer S, Rotman M, Stetz J. Failure of misonidazole-sensitized radiotherapy to impact upon outcome among stage III-IV squamous cancers of the head and neck. Int J Radiat Oncol Biol Phys. 1987 Aug; 13(8):1155-60. PMID: 3301758.
      Citations:    
    114. Leibel SA, Pajak TF, Massullo V, Order SE, Komaki RU, Chang CH, Wasserman TH, Phillips TL, Lipshutz J, Durbin LM. A comparison of misonidazole sensitized radiation therapy to radiation therapy alone for the palliation of hepatic metastases: results of a Radiation Therapy Oncology Group randomized prospective trial. Int J Radiat Oncol Biol Phys. 1987 Jul; 13(7):1057-64. PMID: 3597149.
      Citations:    
    115. Perez CA, Pajak TF, Rubin P, Simpson JR, Mohiuddin M, Brady LW, Perez-Tamayo R, Rotman M. Long-term observations of the patterns of failure in patients with unresectable non-oat cell carcinoma of the lung treated with definitive radiotherapy. Report by the Radiation Therapy Oncology Group. Cancer. 1987 Jun 01; 59(11):1874-81. PMID: 3032394.
      Citations:    
    116. Crissman JD, Pajak TF, Zarbo RJ, Marcial VA, Al-Sarraf M. Improved response and survival to combined cisplatin and radiation in non-keratinizing squamous cell carcinomas of the head and neck. An RTOG study of 114 advanced stage tumors. Cancer. 1987 Apr 15; 59(8):1391-7. PMID: 2434208.
      Citations:    
    117. Jacobs JR, Pajak TF, Kinzie J, Al-Sarraf M, Davis L, Hanks GA, Weigensberg I, Leibel S. Induction chemotherapy in advanced head and neck cancer. A Radiation Therapy Oncology Group Study. Arch Otolaryngol Head Neck Surg. 1987 Feb; 113(2):193-7. PMID: 3541972.
      Citations:    
    118. Al-Sarraf M, Pajak TF, Marcial VA, Mowry P, Cooper JS, Stetz J, Ensley JF, Velez-Garcia E. Concurrent radiotherapy and chemotherapy with cisplatin in inoperable squamous cell carcinoma of the head and neck. An RTOG Study. Cancer. 1987 Jan 15; 59(2):259-65. PMID: 3802013.
      Citations:    
    119. Coleman CN, Halsey J, Cox RS, Hirst VK, Blaschke T, Howes AE, Wasserman TH, Urtasun RC, Pajak T, Hancock S, et al. Relationship between the neurotoxicity of the hypoxic cell radiosensitizer SR 2508 and the pharmacokinetic profile. Cancer Res. 1987 Jan 01; 47(1):319-22. PMID: 3024818.
      Citations:    
    120. Marcial VA, Pajak TF, Chang C, Tupchong L, Stetz J. Hyperfractionated photon radiation therapy in the treatment of advanced squamous cell carcinoma of the oral cavity, pharynx, larynx, and sinuses, using radiation therapy as the only planned modality: (preliminary report) by the Radiation Therapy Oncology Group (RTOG). Int J Radiat Oncol Biol Phys. 1987 Jan; 13(1):41-7. PMID: 3542916.
      Citations:    
    121. Vinciguerra V, Propert KJ, Coleman M, Anderson JR, Stutzman L, Pajak TF, Nissen NI, Frizzera G, Gottlieb A, Holland JF. Alternating cycles of combination chemotherapy for patients with recurrent Hodgkin's disease following radiotherapy. A prospectively randomized study by the Cancer and Leukemia Group B. J Clin Oncol. 1986 Jun; 4(6):838-46. PMID: 2423652.
      Citations:    
    122. Solin LJ, Fowble B, Martz K, Pajak TF, Goodman RL. Results of re-excisional biopsy of the primary tumor in preparation for definitive irradiation of patients with early stage breast cancer. Int J Radiat Oncol Biol Phys. 1986 May; 12(5):721-5. PMID: 3710856.
      Citations:    
    123. Kramer S, Marcial VA, Pajak TF, MacLean CJ, Davis LW. Prognostic factors for loco/regional control and metastasis and the impact on survival. Int J Radiat Oncol Biol Phys. 1986 Apr; 12(4):573-8. PMID: 3516952.
      Citations:    
    124. Maor MH, Schoenfeld DA, Hendrickson FR, Davis LW, Laramore GE, Thomas FJ, Pajak TF. Evaluation of a neutron boost in head and neck cancer. Results of the randomized RTOG trial 78-08. Am J Clin Oncol. 1986 Feb; 9(1):61-6. PMID: 3082179.
      Citations:    
    125. Griffin T, Pajak T, Laramore G, Davis L. Analysis of neutron radiotherapy treatment complications. Bull Cancer. 1986; 73(5):582-6. PMID: 3096403.
      Citations:    
    126. Kurup PD, Pajak TF, Nelson JS, Mansell J, Hendrickson FR, Cohen L, Griffin TW. Fast neutron therapy for malignant astrocytomas. A review. J Neurooncol. 1986; 4(2):123-9. PMID: 3537221.
      Citations:    
    127. Maurer LH, Pajak T, Eaton W, Comis R, Chahinian P, Faulkner C, Silberfarb PM, Henderson E, Rege VB, Baldwin PE, et al. Combined modality therapy with radiotherapy, chemotherapy, and immunotherapy in limited small-cell carcinoma of the lung: a Phase III cancer and Leukemia Group B Study. J Clin Oncol. 1985 Jul; 3(7):969-76. PMID: 2991478.
      Citations:    
    128. Marcial VA, Pajak TF. Radiation therapy alone or in combination with surgery in head and neck cancer. Cancer. 1985 May 01; 55(9 Suppl):2259-65. PMID: 3919930.
      Citations:    
    129. Kurup PD, Pajak TF, Hendrickson FR, Nelson JS, Mansell J, Cohen L, Awschalom M, Rosenberg I, Ten Haken RK. Fast neutrons and misonidazole for malignant astrocytomas. Int J Radiat Oncol Biol Phys. 1985 Apr; 11(4):679-86. PMID: 2984151.
      Citations:    
    130. Danoff BF, Pajak TF, Solin LJ, Goodman RL. Excisional biopsy, axillary node dissection and definitive radiotherapy for Stages I and II breast cancer. Int J Radiat Oncol Biol Phys. 1985 Mar; 11(3):479-83. PMID: 3972660.
      Citations:    
    131. Nelson DF, Nelson JS, Davis DR, Chang CH, Griffin TW, Pajak TF. Survival and prognosis of patients with astrocytoma with atypical or anaplastic features. J Neurooncol. 1985; 3(2):99-103. PMID: 4031977.
      Citations:    
    132. Whittington R, Solin L, Mohiuddin M, Cantor RI, Rosato FE, Biermann WA, Weiss SM, Pajak TF. Multimodality therapy of localized unresectable pancreatic adenocarcinoma. Cancer. 1984 Nov 01; 54(9):1991-8. PMID: 6478433.
      Citations:    
    133. Solin LJ, Danoff BF, Pajak TF, Goodman RL. Breast cancer in young women treated definitively with radiotherapy. An early report. Am J Clin Oncol. 1984 Oct; 7(5):431-5. PMID: 6507363.
      Citations:    
    134. Cooper MR, Pajak TF, Gottlieb AJ, Glicksman AS, Nissen N, Richards F, Bloomfield C, Holland JF. The effects of prior radiation therapy and age on the frequency and duration of complete remission among various four-drug treatments for advanced Hodgkin's disease. J Clin Oncol. 1984 Jul; 2(7):748-55. PMID: 6376718.
      Citations:    
    135. Mohiuddin M, Marks G, Kramer S, Pajak T. Adjuvant radiation therapy for rectal cancer. Int J Radiat Oncol Biol Phys. 1984 Jul; 10(7):977-80. PMID: 6430847.
      Citations:    
    136. Griffin TW, Pajak TF, Gillespie BW, Davis LW, Brady LW, Rubin P, Marcial VA. Predicting the response of head and neck cancers to radiation therapy with a multivariate modelling system: an analysis of the RTOG head and neck registry. Int J Radiat Oncol Biol Phys. 1984 Apr; 10(4):481-7. PMID: 6725038.
      Citations:    
    137. Pilepich MV, Asbell SO, Mulholland GS, Pajak T. Surgical staging in carcinoma of the prostate: the RTOG experience. Radiation Therapy Oncology Group. Prostate. 1984; 5(5):471-6. PMID: 6483687.
      Citations:    
    138. Danoff BF, Goodman RL, Glick JH, Haller DG, Pajak TF. The effect of adjuvant chemotherapy on cosmesis and complications in patients with breast cancer treated by definitive irradiation. Int J Radiat Oncol Biol Phys. 1983 Nov; 9(11):1625-30. PMID: 6417073.
      Citations:    
    139. Green M, Horton C, Spaulding M, Silver RT, Berenberg J, Kennedy BJ, Pajak TF, Comis R. Four-drug combination chemotherapy (methotrexate, cyclophosphamide, hexamethylmelamine, and CCNU) for non-small cell bronchogenic carcinoma: a Cancer and Leukemia Group B study. J Clin Oncol. 1983 Sep; 1(9):559-65. PMID: 6422007.
      Citations:    
    140. Pilepich MV, Pajak T, George FW, Asbell SO, Stetz J, Zinninger M, Plenk HP, Johnson RJ, Mulholland SG, Walz BJ, Kalish L. Preliminary report on phase III RTOG studies of extended-field irradiation in carcinoma of the prostate. Am J Clin Oncol. 1983 Aug; 6(4):485-91. PMID: 6346857.
      Citations:    
    141. Danoff BF, Coia LR, Cantor RI, Pajak TF, Kramer S. Locally recurrent breast carcinoma: the effect of adjuvant chemotherapy on prognosis. Radiology. 1983 Jun; 147(3):849-52. PMID: 6844626.
      Citations:    
    142. Cornwell GG, Pajak TF, Kochwa S, McIntyre OR, Glowienka LP, Brunner K, Rafla S, Silver RT, Cooper MR, Henderson E, Kyle RA, Haurani FI, Cuttner J. Comparison of oral melphalan, CCNU, and BCNU with and without vincristine and prednisone in the treatment of multiple myeloma. Cancer and Leukemia Group B experience. Cancer. 1982 Nov 01; 50(9):1669-75. PMID: 7116299.
      Citations:    
    143. Cooper MR, Pajak TF, Nissen NI, Brunner K, Stutzman L, Bank A, Falkson G, Barker BE, Haurani FI, Richards F, Gottlieb A, Holland JF. Effect of methanol extraction residue of Bacillus Calmette-Guerin in advanced Hodgkin's disease. Cancer. 1982 Jun 01; 49(11):2226-30. PMID: 6804082.
      Citations:    
    144. Chahinian AP, Pajak TF, Holland JF, Norton L, Ambinder RM, Mandel EM. Diffuse malignant mesothelioma. Prospective evaluation of 69 patients. Ann Intern Med. 1982 Jun; 96(6 Pt 1):746-55. PMID: 7091938.
      Citations:    
    145. Ginsberg SJ, Crooke ST, Bloomfield CD, Peterson B, Kennedy BJ, Blom J, Ellison RR, Pajak TF, Gottlieb AJ. Cyclophosphamide, doxorubicin, vincristine, and low-dose continuous infusion bleomycin in non-Hodgkin's lymphoma: Cancer and Leukemia Group B Study No. 7804. Cancer. 1982 Apr 01; 49(7):1346-52. PMID: 6174203.
      Citations:    
    146. Glicksman AS, Pajak TF, Gottlieb A, Nissen N, Stutzman L, Cooper MR. Second malignant neoplasms in patients successfully treated for Hodgkin's disease: a Cancer and Leukemia Group B study. Cancer Treat Rep. 1982 Apr; 66(4):1035-44. PMID: 6951632.
      Citations:    
    147. Bloomfield CD, Pajak TF, Glicksman AS, Gottlieb AJ, Coleman M, Nissen NI, Rafla S, Stutzman L, Vinciguerra V, Glidewell OJ, Holland JF. Chemotherapy and combined modality therapy for Hodgkin's disease: a progress report on Cancer and Leukemia Group B studies. Cancer Treat Rep. 1982 Apr; 66(4):835-46. PMID: 6176320.
      Citations:    
    148. Spaulding MB, Barron SS, Comis RL, Richards F, Kennedy BJ, Pajak TF. Severe neurotoxicity with methyl G: CALGB experience. Med Pediatr Oncol. 1982; 10(5):521-4. PMID: 6292681.
      Citations:    
    149. Cavalli F, Jungi WF, Nissen NI, Pajak TF, Coleman M, Holland JF. Phase II trial of cis-dichlorodiammineplatinum (II) in advanced malignant lymphoma: a study of the cancer and acute leukemia group B. Cancer. 1981 Nov 01; 48(9):1927-30. PMID: 7197582.
      Citations:    
    150. Maurer LH, Pajak TF. Prognostic factors in small cell carcinoma of the lung: a cancer and leukemia group B study. Cancer Treat Rep. 1981 Sep-Oct; 65(9-10):767-74. PMID: 6268294.
      Citations:    
    151. Hansen HH, Selawry OS, Pajak TF, Spurr CL, Falkson G, Brunner K, Cuttner J, Nissen NI, Holland JF. The superiority of CCNU in the treatment of advanced Hodgkin's disease: Cancer and Leukemia Group B Study. Cancer. 1981 Jan 01; 47(1):14-8. PMID: 7006789.
      Citations:    
    152. Cooper MR, Pajak TF, Nissen NI, Stutzman L, Brunner K, Cuttner J, Falkson G, Grunwald H, Bank A, Leone L, Seligman BR, Silver RT, Weiss RB, Haurani F, Blom J, Spurr CL, Glidewell OJ, Gottlieb AJ, Holland JF. A new effective four-drug combination of CCNU (1-[2-chloroethyl]-3-cyclohexyl-1-nitrosourea) (NSC-79038), vinblastine, prednisone, and procarbazine for the treatment of advanced Hodgkin's disease. Cancer. 1980 Aug 15; 46(4):654-62. PMID: 7397630.
      Citations:    
    153. Chlebowski RT, Silverberg I, Pajak T, Weiner J, Kardinal C, Bateman JR. Treatment of advanced colon cancer with 5-fluorouracil (NSC19893) versus cyclophosphamide (NSC26271) plus 5-fluorouracil: prognostic aspects of the differential white blood cell count. Cancer. 1980 May 01; 45(9):2240-4. PMID: 6991095.
      Citations:    
    154. Nissen NI, Pajak TF, Leone LA, Bloomfield CD, Kennedy BJ, Ellison RR, Silver RT, Weiss RB, Cuttner J, Falkson G, Kung F, Bergevin PR, Holland JF. Clinical trial of VP 16--213 (NSC 141540) I.V. twice weekly in advanced neoplastic disease: a study by the Cancer and Leukemia Group B. Cancer. 1980 Jan 15; 45(2):232-5. PMID: 6985831.
      Citations:    
    155. Maurer LH, Tulloh M, Weiss RB, Blom J, Leone L, Glidewell O, Pajak TF. A randomized combined modality trial in small cell carcinoma of the lung: comparison of combination chemotherapy-radiation therapy versus cyclophosphamide-radiation therapy effects of maintenance chemotherapy and prophylactiv whole brain irradiation. Cancer. 1980 Jan 01; 45(1):30-9. PMID: 6243242.
      Citations:    
    156. Reynolds RD, Pajak TF, Bateman JR, Greenberg BR, Sun NC, Frank JG, Shirley JH, Lucas RN, O'Dell SE. Considerations in designing and analyzing surgical adjuvant study in resected stage I and II carcinoma of the lung. Cancer. 1979 Oct; 44(4):1201-10. PMID: 227557.
      Citations:    
    157. Nissen NI, Pajak TF, Glidewell O, Pedersen-Bjergaard J, Stutzman L, Falkson G, Cuttner J, Blom J, Leone L, Sawitsky A, Coleman M, Haurani F, Spurr CL, Harley JB, Seligman B, Cornell C, Henry P, Senn HJ, Brunner K, Martz G, Maurice P, Bank A, Shapiro L, James GW, Holland JF. A comparative study of a BCNU containing 4-drug program versus MOPP versus 3-drug combinations in advanced Hodgkin's disease: a cooperative study by the Cancer and Leukemia Group B. Cancer. 1979 Jan; 43(1):31-40. PMID: 367570.
      Citations:    
    158. Reynolds RD, Pajak TF, Greenberg BR, Shirley JH, Lucas RN, Hill RP, Schacht LR. Lung cancer as a second primary. Cancer. 1978 Dec; 42(6):2887-93. PMID: 215300.
      Citations:    
    159. Kung FH, Nythan WL, Cuttner J, Falkson G, Lanzkowsky P, Del Duca V, Nawabi IU, Koch K, Pluess H, Freeman A, Burgert EO, Leone LA, Ruymann F, Patterson RB, Degnan T, Hakami N, Pajak TF, Holland J. Vincristine, prednisone and L-asparaginase in the induction of remission in children with acute lymphoblastic leukemia following relapse. Cancer. 1978 Feb; 41(2):428-34. PMID: 272945.
      Citations:    
    160. Nissen NI, Pajak T, Glidewell O, Blom H, Flaherty M, Hayes D, McIntyre R, Holland JF. Overview of four clinical studies of chemotherapy for stage III and IV non-Hodgkin's lymphomas by the Cancer and Leukemia Group B. Cancer Treat Rep. 1977 Sep; 61(6):1097-107. PMID: 71208.
      Citations:    
    161. Lewis JP, Linman JW, Marshall GJ, Pajak TF, Bateman JR. Randomized clinical trial of cystosine arabinoside and 6-thioguanine in remission induction and consolidation of adult nonlymphocytic acute leukemia. Cancer. 1977 Apr; 39(4):1387-96. PMID: 322835.
      Citations:    
    162. Durkin WJ, Pugh RP, Jacobs E, Sadoff L, Pajak T, Bateman JR. Bleomycin (NSC-125066) therapy of responsive solid tumors. Oncology. 1976; 33(5-6):260-4. PMID: 68454.
      Citations:    
    163. Durkin WJ, Pugh RP, Solomon J, Rosen P, Pajak TF, Bateman JR. Treatment of advanced lymphomas with bleomycin (NSC-125066). Oncology. 1976; 33(3):140-5. PMID: 64951.
      Citations:    
    164. Richards F, Spurr CL, Pajak TF, Blake DD, Raben M. Thymic irradiation. An approach to chronic lymphocytic leukemia. Am J Med. 1974 Dec; 57(6):862-9. PMID: 4432870.
      Citations:    
    165. Richards F, Pajak TF, Cooper MR, Spurr CL. Study of methyl-CCNU(NSC-95441) in the treatment of lung cancer. Cancer Chemother Rep. 1973 Nov-Dec; 57(4):419-22. PMID: 4357670.
      Citations:    
    Pajak's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (389)
    Explore
    _
    Co-Authors (10)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _